icobrain dm 了解更多
销售价格： ￥ N/A
商品编号： AI-0132-0382
软件语言： 英文
器械分类： II
生产厂家： icometrix
公司网址： https://icometrix.com/
认证信息： FDA
系统要求： Windows
交付方式： 下载安装
  • 软件概览
  • 推荐配置
  • 典型病例
  • 软件教程
  • 临床文献
  • 用户评价
  • 产品彩页

软件概览

Dementia and Alzheimer's

Supporting differential diagnosis and monitoring of atrophy in dementia


icobrain dm

icobrain dm is designed to support the early detection of markers of dementias, comparing whole brain and ventricular volumes to age- and sex-matched healthy controls. 

icobrain dm can also used to assist radiologists and neurologists with the differential diagnosis of the particular type of dementia a patient may have, by providing individual volumes of the cortical lobes and hippocampi, and reporting percentiles compared to the age- and sex-matched healthy control population.

Additionally, icobrain dm can help radiologists and neurologists to evaluate eligibility for amyloid-targeting treatments for Alzheimer's disease, by reporting out the total volume of FLAIR white matter hyperintensities, as well as the number of T2* GRE hypointensities.

1754230418879.png


Dr. Johan Van Goethem on his experience with icobrain dm

1754230440281.png

Click to watch the video


icobrain aria

icobrain aria is used to assess side effects to amyloid-targeting therapies for Alzheimer's disease, known as amyloid-related imaging abnormalities (ARIA). It detects edema (gyral swelling and sulcal effusion), microhemorrhages, and superficial siderosis.

1754230478228.png


ARIA in Alzheimer’s Care - Insights from Experts at ECR2025

1754230516219.png

Click to watch the video

1754230556970.png


Key scientific publications

Independent validation and outlier analysis of EuroPOND alzheimer’s disease staging model using ADNI and real-world clinical data

Wittens et al. (2025)

Brain age as a biomarker for pathological versus healthy ageing – a REMEMBER study

Wittens et al. (2024)

A deep learning model for brain segmentation across pediatric and adult populations

Simarro et al. (2024)

Combining semi-quantitative rating and automated brain volumetry in MRI evaluation of patients with probable behavioural variant of fronto-temporal dementia: an added value for clinical practise?

Calloni et al. (2023)

Cost-Effectiveness Analysis of AI-Assisted Radiological Assessment in Patients With Relapsing Remitting Multiple Sclerosis in the UK

Esposito et al. (2022)

Inter- and Intra-Scanner Variability of Automated Brain Volumetry on Three Magnetic Resonance Imaging Systems in Alzheimer’s Disease and Controls

Wittens et al. (2021)

Diagnostic Performance of Automated MRI Volumetry by icobrain dm for Alzheimer's Disease in a Clinical Setting: A REMEMBER Study

Wittens et al. (2021)

Health Economic Impact of Software-Assisted Brain MRI on Therapeutic Decision-Making and Outcomes of Relapsing-Remitting Multiple Sclerosis Patients—A Microsimulation Study

Sima et al. (2021)

Towards validation in clinical routine: a comparative analysis of visual MTA ratings versus the automated ratio between inferior lateral ventricle and hippocampal volumes in Alzheimer’s disease diagnosis

Wittens et al. (2024)

Key scientific publications

Independent validation and outlier analysis of EuroPOND alzheimer’s disease staging model using ADNI and real-world clinical data

Wittens et al. (2025)

Brain age as a biomarker for pathological versus healthy ageing – a REMEMBER study

Wittens et al. (2024)

A deep learning model for brain segmentation across pediatric and adult populations

Simarro et al. (2024)

Combining semi-quantitative rating and automated brain volumetry in MRI evaluation of patients with probable behavioural variant of fronto-temporal dementia: an added value for clinical practise?

Calloni et al. (2023)

Cost-Effectiveness Analysis of AI-Assisted Radiological Assessment in Patients With Relapsing Remitting Multiple Sclerosis in the UK

Esposito et al. (2022)

Inter- and Intra-Scanner Variability of Automated Brain Volumetry on Three Magnetic Resonance Imaging Systems in Alzheimer’s Disease and Controls

Wittens et al. (2021)

Diagnostic Performance of Automated MRI Volumetry by icobrain dm for Alzheimer's Disease in a Clinical Setting: A REMEMBER Study

Wittens et al. (2021)

Health Economic Impact of Software-Assisted Brain MRI on Therapeutic Decision-Making and Outcomes of Relapsing-Remitting Multiple Sclerosis Patients—A Microsimulation Study

Sima et al. (2021)

Towards validation in clinical routine: a comparative analysis of visual MTA ratings versus the automated ratio between inferior lateral ventricle and hippocampal volumes in Alzheimer’s disease diagnosis

Wittens et al. (2024)


推荐配置


典型病例


软件教程


临床文献


用户评价

I feel like icobrain’s AI is better at diagnosing hippocampal loss compared to visual rating. Whilst with the volumetric report, we clearly see a hippocampal loss, we could not identify this by visual assessment (MTA-score)

I feel like icobrain’s AI is better at diagnosing hippocampal loss compared to visual rating. Whilst with the volumetric report, we clearly see a hippocampal loss, we could not identify this by visual assessment (MTA-score)

Geoffrey De Roeck, Radiologist at AZ Herentals

Like icobrain, brain biomarker measurements need to be extremely reproducible and sensitive enough to detect relevant clinical changes.

Like icobrain, brain biomarker measurements need to be extremely reproducible and sensitive enough to detect relevant clinical changes.

Max Wintermark, Radiologist at Stanford University


产品彩页


请完善个人信息

非常抱歉，您只有购买软件后才能查看完整软件教程！

看了此商品的会员还在看
测试版
版本号 软件大小 下载地址
01 1m 下载
正式版
版本号 软件大小 下载地址
01 1m 下载